Insurance Coverage: Many major insurance plans no longer cover Invokana. Learn More
Tori Marsh - June 14, 2018
Brand drugs are expensive — this we already know, and prices seem to only be increasing. Of the 100 most-prescribed brand-name medications, those for diabetes, rheumatoid arthritis, and Crohn’s disease tend to be the most expensive. All of the drugs on this list are brand-only medications, meaning that there are no affordable generic alternatives available.
Additionally, it can be difficult for people to receive adequate insurance coverage for many of these drugs as they may be placed in more expensive, higher-tier formularies or have some other coverage restrictions. See More
Roni Shye - January 16, 2018
If you’ve ever been afraid to show up at your doctor’s office because you’ve been “bad” then this post is for YOU! You may think your doctor is “pushing medications on you” especially if you aren’t experiencing any symptoms of the condition they are treating you for. However, their reasoning is not without sound medical and professional judgment.
One of the many reasons you might receive a lecture about the importance of taking your medications is due to the progressive nature of many diseases if not properly treated. See More
Roni Shye - June 21, 2017
This update is the result of new data from the CANVAS and CANVAS-R clinical trials. This research showed that leg and foot amputations occurred two times more often in patients treated with canagliflozin than in patients who were given a placebo sugar pill. See More
Roni Shye - July 06, 2016
According to the FDA, canagliflozin and dapagliflozin may cause an increased risk of acute kidney injury. The previous warning for canagliflozin was for an increased risk of foot and leg amputations—all serious stuff. See More
Roni Shye - June 08, 2016
The FDA has issued a safety alert for medications containing canagliflozin, a newer drug used to treat type 2 diabetes.
Do diabetics already have an increased risk of leg and foot amputations?
Yes. Diabetics have a higher risk of leg and foot amputations compared to a person who does not have diabetes. See More
Elizabeth Davis - August 12, 2015
It’s that time again—the new lists of covered and excluded drugs on next year’s insurance plans are out, and it doesn’t look great. For many Americans with health insurance, more than 50 popular brand-name and generic drugs may no longer be covered starting in January 2016.
Express Scripts and Caremark, companies that handles pharmacy benefits for more than 200 million Americans, are removing about 20 – 30 drugs each from their national preferred formularies at the end of 2015. See More
Roni Shye - May 21, 2015
On May 15, 2015, the FDA issued a warning for the newest class of diabetes medications, SGLT2 inhibitors.
According to the FDA, the medications in this class may lead to a serious and life-threatening condition known as ketoacidosis.
Which medications are considered SGLT2 inhibitors?
These medications also contain SGLT2 inhibitors in combination with other active ingredients:
- Glyxambi (empagliflozin/linagliptin)
- Invokamet (canagliflozin/metformin)
- Xigduo XR (dapagliflozin/metformin)
What should I do if I am taking one of these medications?
If you are taking one of the medications listed above DO NOT stop your medication without talking to your doctor. See More
Dr. Sharon Orrange - September 30, 2014
Invokana (canagliflozin) is one of the new oral medications for adult onset diabetes. It’s expensive but has many upsides. Taken usually in combination with metformin it is a rising star in the treatment of diabetes. Here is what you need to know to help you decide: worth it or not?
Roni Shye - August 08, 2014
Jardiance (empagliflozin) was approved by the FDA on August 1, 2014 for the treatment of type 2 diabetes.
How does Jardiance work?
It works with the body’s natural process of urination to help remove more excess sugar from the body rather than allowing it to be reabsorbed by your kidneys. See More
Roni Shye - January 10, 2014
Farxiga (dapagliflozin) was approved by the FDA for the treatment of type II diabetes this week, after a previous denial in January 2012 due to bladder cancer concerns. Here’s what you need to know:
How does Farxiga work, and are there any similar drugs available?
Dapagliflozin is part of a newer class of drugs: Sodium Glucose Co-Transporter 2 inhibitors (SGLT2 inhibitors). Invokana (canagliflozin), approved in March 2013, is the only other medication in this class. See More